Scientific Advisory Board



A Scientific Advisory Board and Clinical Collaborators Strategy is one of the key strategic activities implemented by a medical company. That has been consistent with the increased emphasis on evidence-based, goal-directed medicine with adherence to  clinical guidelines for adoption of any new product. It is also critical in demonstrating an understanding of the health economic impact of any new product.

We are very pleased to have the following clinical leaders advising the company in our scientific and clinical objectives, as we strive to improve the diagnosis and management of this complex disease process:

Chaim Putterman, M.D., Chair, is Professor of Medicine and Microbiology & Immunology, and Chief of the Division of Rheumatology at the Albert Einstein College of Medicine and Montefiore Medical Center (Bronx, New York). Dr. Putterman’s major research interests are in the field of immunology and autoimmune diseases, and specifically the identification and characterization of novel mechanisms, biomarkers, and treatment approaches to inflammatory arthritis and systemic lupus erythematosus.

Dr. Putterman’s laboratory has received funding from the National Institute of Health, Alliance for Lupus Research, Lupus Research Institute, Arthritis Foundation, and Biogen Idec. He has published more than 160 articles and book chapters in the medical and scientific literature. He was elected to the American Society of Clinical Investigation, and is a member of the American College of Rheumatology and the American Association of Immunologists. Dr. Putterman has served on multiple NIH and international study sections, and is currently a member of several editorial boards.

Ignacio Sanz, M.D. Director for the Division of Rheumatology and the Chair of the Lowance Center for Human Immunology at Emory University, where he also is a Tenured Professor of Medicine and Pediatrics and serves as the director for the Division of Rheumatology and the Chair of the Lowance Center for Human Immunology.  Previously, he was a Tenured Professor of Medicine & Immunology at the University of Rochester School of Medicine and Dentistry where he had been the Chief of the Division of Allergy, Immunology and Rheumatology since 1996. He received his M.D degree from the University of Santander in Spain and did his Immunology and Rheumatology fellowships at the University of Texas Southwestern Medical School in Dallas and at the University of Texas Health Science Center in San Antonio, respectively.  Dr. Sanz’s research is focused on the role of B cells in human disease with particular emphasis on autoimmune diseases.

Jill P. Buyon, M.D. Professor of Medicine and Director of the Division of Rheumatology at New York University School of Medicine. As director of the NYU Lupus Center, she is internationally recognized as a researcher and clinician specializing in the treatment of systemic lupus erythematosus, neonatal lupus, and rheumatic diseases in pregnancy. She has published more than 200 papers in peer-reviewed science journals, co-authored a book on autoimmune diseases in women written for a lay audience, and was editor of the 5th edition of the comprehensive reference textbook, “Systemic Lupus Erythematosus.”  She was recently named editor of the new online journal “Lupus Science and Medicine.”  She led the first multicenter study in SLE that resulted in a paradigm change with regard to the safety of contraceptive estrogens.

Dr. Buyon received her medical degree from the Albert Einstein College of Medicine, New York, NY.  She pursued postgraduate training at the Bronx Municipal Hospital Center, New York University Medical Center, and the Hospital for Joint Diseases (HJD).  As a postdoctoral fellow at HJD in 1985, Dr. Buyon founded the HJD Lupus Clinic, and has since served as its director. Dr. Buyon’s honors include Alpha Omega Alpha and the Fabian Award for Excellence in Research.  She also received a Kirkland Scholar Award, a Distinguished Clinical Investigator Award from the American College of Rheumatology, and the Evelyn V. Hess Lifetime Achievement Award for Research in Lupus from the Lupus Foundation of America.  Dr. Buyon is a fellow of the American College of Rheumatology and is responsible for the annual organization of the Lupus Study Group.

David S. Pisetsky, M.D., Ph.D., Professor of Medicine and Immunology, Duke University Medical Center. He received his B.A. from Harvard College magna cum laude in 1967 and his Ph.D. and M.D. degrees from the Albert Einstein College of Medicine in 1972 and 1973.  He was an intern and resident in Internal Medicine at the Yale-New Haven Hospital from 1973-1975.  From 1975-1978, he was a clinical associate at the National Cancer Institute, studying the immune response to protein antigens.  He joined the faculty of the Duke University Medical Center in 1978 as Chief of Rheumatology at the Durham VA Hospital where he has remained since.  He served as Chief of Rheumatology at Duke from 1996-2007.

Dr. Pisetsky has conducted basic and translational research on the pathogenesis of systemic lupus erythematosus (SLE), focusing on the generation of antinuclear antibodies and the immunological properties of nuclear macromolecules.  His studies were among the first to establish the antigenic and mitogenic activity of bacterial DNA, the antigenicity of oligonucleotides and the ability of synthetic oligonucleotides to modulate immune responses.  More recently, he has investigated the release of DNA and related nuclear molecules during cell death.  He also is studying the activity of nucleic acid binding polymers (NABPs) as a way to block immune responses induced by DNA and RNA.

Dr. Pisetsky has had grant funding from the NIH, Veterans Administration and various foundations.  He has published over 350 articles and chapters and has edited several textbooks and volumes.  From 2000-2005, he served as editor of Arthritis and Rheumatism and was the first Physician Editor of The Rheumatologist from 2006-2011. He is currently on the editorial board of Annals of Rheumatic Disease and Arthritis Research and Therapy.  He continues to see patients at the Durham VA Hospital.

Mary Collins, PhD is a scientific leader in the biopharmaceutical industry with 28 years of experience leading research efforts to discover and develop new small molecule and protein therapeutics for the treatment of inflammatory diseases. She currently serves on the Scientific Advisory Board of the Lupus Research Institute, is a visiting scientist at Harvard Medical School and consults for small biotechnology companies.

Dr. Collins served as Chief Scientific Officer of the Immunology and Autoimmunity Research Unit for Pfizer in Cambridge MA from 2009 until her retirement in 2011. Prior to this, she was Vice President of Inflammation Discovery Research at Wyeth. She had responsibility for teams of up to 130 scientists focused on RA, SLE, Psoriasis, MS and IBD and advanced multiple therapeutic candidates to Phase 1 and Phase 2 clinical trials.

Dr. Collins completed undergraduate, graduate and postdoctoral work at SUNY at Stony Brook, Wesleyan University, and the Carnegie Institute of Washington. She joined Genetics Institute in 1983, and began work in Immunology in 1987 after a sabbatical at Harvard Medical School. She joined Wyeth in 1996 and Pfizer in 2009 following corporate acquisitions. Dr. Collins is an author on 100 publications and an inventor on 35 issued U.S. patents. She enjoys collaborative interactions with scientists in the Immunology community, making scientific contributions to the field, mentoring the next generation of scientists, and contributing to improvements in healthcare.